Nanoshell has enjoyed the support of the National Institutes of Health, NHLBI and Centers for Disease Control for several development projects. These include development of a retrievable artificial oxygen carrier system, sensors for the early sensitive detection of fungal infections, and received over a comprehensive transfusion therapy for patients with hemolytic blood conditions. Since 2009 we have received over $3 million dollars in Federal support at both the Phase I and Phase II levels. We are in the midst of filing FDA paperwork for investigational use of these technologies and non-medical versions of these are expects to be on the market in late 2017/early 2018.